APRINOIA Therapeutics finances US$11.1 Million Series B for developing imaging diagnostic and therapeutic pipelines
APRINOIA Therapeutics into tau, alpha-synuclein, and novel targets for neurodegenerative diseases declared the completion of its US$11.1 million Series B round to finance preclinical and clinical development for APRINOIA’s imaging diagnostic and therapeutic pipelines.
The Company’s most advanced tau PET imaging tracer, 18F-PM-PBB3, has shown great potential in visualizing tau pathologies in Alzheimer’s and Progressive Supranuclear Palsy (PSP) patients in clinical studies conducted in early 2017 and the results have been well-received.
Ming-Kuei Jang, founder and CEO of APRINOIA. “We are also very excited about the progress we have made with our therapeutic platforms. We are building collections of small molecules and antibodies with diverse properties and therapeutic potentials. We are fortunate to have dedicated teams, collaborators, and investors working together to find comprehensive solutions for our research and medical communities, and ultimately for our patients.”
APRINOIA previously raised the total of US$6.4 million in its Seed and Series A round, which supported the completion of preclinical development and the initiation of clinical development for its 2nd generation tau PET imaging tracer, 18F-PM-PBB3, in the USA and in Japan. The Company has invested extensively in building a strong R&D team for executing its current and future pipeline development, including a 3rd generation tau PET imaging tracer, alpha-synuclein PET imaging tracer, and two distinctive therapeutic programs.